28 research outputs found
Cardiomyopathy Following High Dose Melphalan Conditioning Prior to Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma and Primary Amyloidosis
100: Fluid Related Complications with Filgrastim (G-CSF) 10 mcg/kg Once Daily Versus 5 mcg/kg Twice Daily in Amyloidosis Patients Undergoing Peripheral Blood Stem Cell Mobilization
138Lymphocyte recovery after allogeneic stem cell transplantation: Comparison of bone marrow and peripheral blood stem cell transplantation
CD34+ Cell Dose and Full Donor Chimerism at Day +100 Is Associated with Survival in Patients Who Received Reduced-Intensity Conditioning (RIC) With Fludarabine/Melphalan Prior To Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies
Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains
Cast nephropathy is the most common cause of renal disease in multiple myeloma, however, treatment with plasma exchange remains controversial even after 3 randomized controlled studies. We sought to determine the importance of diagnostic confirmation and goal directed therapy in the treatment of cast nephropathy in forty patients with confirmed multiple myeloma and renal failure who underwent plasma exchange. A positive renal response was defined as a decrease by half in the presenting serum creatinine and dialysis independence. No baseline differences were noted between eventual renal responders and non-responders. Three quarters of the patients with biopsy proven cast nephropathy resolved their renal disease when the free light chains present in the serum were reduced by half or more but there was no significant response when the reduction was less. The median time to a response was about 2 months. In patients without cast nephropathy, renal recovery occurred despite reductions in free light chain levels of the serum. No association was found between free light chains in the serum, urinary monoclonal proteins, overall proteinuria and cast nephropathy. We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease
Randomized phase III trial of consolidation therapy with bortezomib–lenalidomide–Dexamethasone (VRd) vs bortezomib–dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen
Long-awaited results from the the Southwest Oncology Group (SWOG) trial comparing bortezomib–lenalidomide-dexamethasone (VRd) versus lenalidomide-dexamethasone (Rd) as induction treatment for previously untreated multiple myeloma (MM) patients were recently presented (S0777).1 Results justified the early adoption of VRd in the frontline setting over 5 years ago by the NCCN based on Level 2A evidence according to their guidelines.2 The randomized study E1A05 also sought to evaluate VRd superiority over a doublet (Vd), but in the consolidation setting. The trial was closed to enrollment prematurely due to slow accrual. Results reported here include 48 enrolled patients.This study was coordinated by the ECOG-ACRIN Cancer Research Group (Robert L
Comis, MD, and Mitchell D Schnall, MD, PhD, Group Co-Chairs) and supported by the
National Cancer Institute of the National Institutes of Health under award numbers:
CA180820, CA180794, CA21115, CA23318, CA66636, CA180790, CA13650, CA189956,
CA35412, CA15488, CA180799 and CA21076.http://www.sherpa.ac.uk/romeo/issn/2044-5385/am2016Medical Oncolog